Floatz logo

METHOTREXATE

Optic Neuritis

MidAmerica Neuroscience Research Foundation at Rowe Neurology InstituteSmall moleculePhase 4 / ApprovedDormant
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Optic Neuritis cohort.

Asset / SponsorPhaseRating
Interferon ?1 (human fibroblast protein moiety)
MidAmerica Neuroscience Research Foundation at Rowe Neurology Institute
Phase 4BB
Fampridine
Courtney Casserly
Phase 2/3BB
Privosegtor
Oculis
Phase 3B
SIMVASTATIN
Glostrup University Hospital, Copenhagen
Phase 3B
PREDNISONE TABLETS
National Eye Institute (NEI)
Phase 3B

View all 15 →

Same molecule, other indications

METHOTREXATE is also rated in:

adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
79 / 100
View asset →
B-cell childhood acute lymphoblastic leukemiaDormant
BBB
Indicative ·
78 / 100
View asset →
acute promyelocytic leukemiaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →